During 2018 Q4 the big money sentiment decreased to 0.9. That’s change of 0.31, from 2018Q3’s 1.21. 35 investors sold all, 44 reduced holdings as PTLA ratio is negative. 50 increased holdings while 21 funds took holdings. Funds hold 63.72 million shares thus 3.36% less from 2018Q3’s 65.93 million shares. Hartwell J M Ltd Partnership reported 34,250 shs stake. Sector Gamma As, Norway-based fund reported 284,701 shs. 5,426 are held by Ameritas Prns. California Employees Retirement owns 76,700 shs or 0% of their US capital. Hightower Advisors Limited Liability Co owns 16,855 shs. Public Employees Retirement Association Of Colorado owns 11,029 shs. 222,200 are held by Canada Pension Plan Board. Barclays Public reported 0% stake. California State Teachers Retirement Systems reported 101,984 shs. Ubs Asset Americas Inc invested in 353,080 shs or 0% of the stock. Susquehanna Grp Incorporated Limited Liability Partnership holds 260,035 shs or 0% of its capital. Rhumbline Advisers owns 87,962 shs. Northwestern Mutual Wealth Management owns 16 shs for 0% of their capital. Bnp Paribas Arbitrage owns 0% invested in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) for 3,304 shs. Ecor1 Capital Limited Liability invested 0.48% of its capital in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA).

PTLA had 1 sale and 0 buys since December 17, 2018. This’s net activity of $1.20 million.

Rosenblum Silverman Sutton S F Inc’s holdings in Saia Inc. (PTLA) is reduced by 84.05% based on its latest 2018Q4 regulatory filing with the SEC. By selling 124,705 shares Rosenblum Silverman Sutton S F Inc made the stock popped up with 59.12%. The health care company at the end of 2018Q4 was valued at $1.32M. It’s down from 148,370 at the end of the previous reported quarter. Now it had 23,665 shares held by the institutional investor . $2.32B is Saia Inc.’s MC. Ticker’s shares touched $34.7 during the last trading session after 3.30% change.Portola Pharmaceuticals, Inc. has volume of 1.09 million shares. Since March 29, 2018 PTLA has risen 5.58% and is uptrending. The stock outperformed the S&P500 by 1.21%.

A portfolio of $291.11 million and $219.36 million is managed by Rosenblum Silverman Sutton S F Inc. As it’s reported in Securities and Exchange filling the stake in Facebook Inc. Class A (NYSE:EXP) is increased by 59,689 shares to 70,934 shares. They are valued at $9.30 million in 2018Q4. Rosenblum Silverman Sutton S F Inc has risen its stake in Salesforce.Com and also increased its holding in Microsoft (NYSE:MRK) by 78,685 shares in the quarter, for a total of 82,436 shares.

On May, 8 is expected Portola Pharmaceuticals, Inc. (NASDAQ:PTLA)’s earnings report, as reported by RTT. Last year’s EPS was $-1.28, while now analysts expect change of 20.31 % up from current $-1.02 EPS. Wall Street now forecasts -1.92 % EPS growth despite Portola Pharmaceuticals, Inc. previous quarter’s EPS of $-1.04.

For more Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) news posted recently go to: Seekingalpha.com, Benzinga.com, Nasdaq.com, Seekingalpha.com or Seekingalpha.com. The titles are as follows: “Portola Pharma’s co-founder retires – Seeking Alpha” posted on March 21, 2019, “30 Stocks Moving In Friday’s Pre-Market Session – Benzinga” on March 01, 2019, “First Week of PTLA April 18th Options Trading – Nasdaq” with a publish date: February 26, 2019, “Portola Pharmaceuticals Q4 Earnings Preview – Seeking Alpha” and the last “Can You Win With Portola Pharmaceutical Options? – Seeking Alpha” with publication date: March 25, 2019.

Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) Ratings Coverage

A total of 4 analysts rate Portola Pharmaceuticals (NASDAQ:PTLA) as follows: 3 “Buy”, 1 “Hold” and 0 “Sell”. Тherefore 75% are bullish. (NASDAQ:PTLA) has 6 ratings reports on Mar 29, 2019 according to StockzIntelligence. The company rating was maintained by Morgan Stanley on Monday, March 4. On Monday, March 4 the company was maintained by Citigroup. In Monday, March 4 report Oppenheimer maintained it with “Buy” rating and $42 target. On Monday, March 4 the stock of Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) earned “Hold” rating by Credit Suisse. On Thursday, November 8 Credit Suisse maintained Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) rating. Credit Suisse has “Neutral” rating and $30 target. In Thursday, October 11 report Morgan Stanley maintained it with “Equal-Weight” rating and $32 target.